Jennifer Gotta, Leon D Gruenewald, Katrin Eichler, Simon S Martin, Scherwin Mahmoudi, Christian Booz, Teodora Biciusca, Philipp Reschke, Simon Bernatz, Daniel Pinto Dos Santos, Jan-Erik Scholtz, Leona S Alizadeh, Nour-Eldin A Nour-Eldin, Renate M Hammerstingl, Tatjana Gruber-Rouh, Christoph Mader, Stefan E Hardt, Christof M Sommer, Giuseppe Bucolo, Tommaso D'Angelo, Melis Onay, Fabian Finkelmeier, David M Leistner, Thomas J Vogl, Evangelos Giannitsis, Vitali Koch
BACKGROUND: Cancer is a well-known risk factor for venous thromboembolism (VTE). A combined strategy of D-dimer testing and clinical pre-test probability is usually used to exclude VTE. However, its effectiveness is diminished in cancer patients due to reduced specificity, ultimately leading to a decreased clinical utility. This review article seeks to provide a comprehensive summary of how to interpret D-dimer testing in cancer patients. METHODS: In accordance with PRISMA standards, literature pertaining to the diagnostic and prognostic significance of D-dimer testing in cancer patients was carefully chosen from reputable sources such as PubMed and the Cochrane databases...
October 2023: European Journal of Clinical Investigation